Abstract:BACKGROUND:Neoadjuvant chemotherapy (NAC) is an effective therapeutic regimen for patients with breast cancer. However, some individuals cannot benefit from NAC because of drug resistance. To date, valid strategies about enhancing sensitivity of breast cancer to NAC are still scarce. miRNAs have been reported to proverbially be involved in the onset and development of malignancies including drug resistance.METHODS:GSE73736 was downloaded from the GEO database. Student's t-test was conducted to acquire differentially expressed-miRNAs (DE-miRNAs). Potential target genes of DE-miRNAs were predicted by miRTarBase. Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses for these target genes were performed by database for annotation, visualization, and integrated discovery. Protein-protein interaction network was constructed by STRING database and visualized through Cytoscape software. The hub target gene-miRNA network was also established by Cytoscape software. Next, the expression of potential functional miRNAs in breast cancer cell lines and tissues was determined. Finally, the roles of miR-3617-3p, miR-3136-3p, and miR-520b in modulating breast cancer chemoresistance were further examined.RESULTS:A total of 123 DE-miRNAs were identified, including 60 upregulated miRNAs and 63 downregulated miRNAs in the chemoresistant breast cancer group when compared with the chemosensitive group. Six hundred and seventeen and 1,146 potential target genes for the top 10 most upregulated and downregulated miRNAs were predicted, respectively. Enrichment analyses revealed that these target genes were enriched in some cancer-associated or chemo-resistance-associated pathways, such as MAPK signaling pathway, wnt signaling pathway, and p53 signaling pathway. MAPK1 and PRDM10 were identified as hub genes in the protein-protein interaction network. The top 25 hub genes were potentially regulated by 16 DE-miRNAs, among which miR-3617-3p and miR-3136-3p were commonly upregulated, whereas miR-520b was downregulated in two chemoresistant breast cancer cells compared with chemosensitive cell. By analyzing TCGA data, we found that expression of miR-3136-3p and miR-520b was increased and decreased in breast cancer tissues, respectively. Moreover, functional experiments demonstrated that miR-3136-3p and miR-3617-3p could reduce chemosensitivity of breast cancer, whereas miR-520b could reverse chemoresistance.CONCLUSION:The present study, based on bioinformatics analysis and experimental validation, brings to light novel mechanisms of breast cancer NAC resistance.

MiR-1268b Confers Chemosensitivity in Breast Cancer by Targeting ERBB2-mediated PI3K-AKT Pathway

Upregulation of Mir-129-5p Increases the Sensitivity to Taxol Through Inhibiting HMGB1-mediated Cell Autophagy in Breast Cancer MCF-7 Cells

MiR-126 Enhances Cisplatin Chemosensitivity in Hepatocellular Carcinoma Cells by Targeting IRS1

Circulating MiR-125b As a Marker Predicting Chemoresistance in Breast Cancer

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

miR-1296-5p decreases ERBB2 expression to inhibit the cell proliferation in ERBB2-positive breast cancer

MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer.

Identification of Chemoresistance-Associated Mirnas in Breast Cancer

miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells

MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway

MicroRNA-1297 Contributes to Tumor Growth of Human Breast Cancer by Targeting PTEN/PI3K/AKT Signaling

MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.

MiR-93 Suppresses Tumorigenesis and Enhances Chemosensitivity of Breast Cancer Via Dual Targeting E2F1 and CCND1.

miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A

Mir-126-5p Affects the Chemosensitivity of Colorectal Cancer Cells by Regulating SPRED1,ERK1/2 Pathway and Apoptosis

MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors

MiR-450b-5p enhances the radiosensitivity of HR+ and HER2− breast cancer by targeting CDK6

Endothelial-specific Intron-Derived Mir-126 is Down-Regulated in Human Breast Cancer and Targets Both VEGFA and PIK3R2

MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer